EGA studies in recent papers

02 March 2026

Comprehensive genomic profiling of triple-negative breast cancer metastases identifies role of PKD1 in immunotherapy resistance.

Published in:

Paper Image

Within this research, the following studies were reused from the EGA:

26 February 2026

Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial.

Published in:

Paper Image

Within this research, the following studies were deposited at EGA:

24 February 2026

Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis.

Published in:

Paper Image

Within this research, the following studies were reused from the EGA:

04 February 2026

Identifying drug targets for schizophrenia through gene prioritization.

Published in:

Paper Image

Within this research, the following studies were reused from the EGA:

04 February 2026

Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.

Published in:

Paper Image

Within this research, the following studies were deposited at EGA:

03 February 2026

Integrating natural and engineered genetic variations to decode regulatory influence on blood traits.

02 February 2026

Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling.

Published in:

Paper Image

Within this research, the following studies were deposited at EGA:

01 February 2026

Integrative Multiomics and Drug Sensitivity Profiling Reveal Potential Biomarkers and Therapeutic Strategies in Pediatric Solid Tumors.